# The Prognostic Value of Sequential ^{18}F-FDG PET/CT Metabolic Parameters in Outcomes of Upper-Third Esophageal Squamous Cell Carcinoma Patients Treated with Definitive Chemoradiotherapy

Le Ngoc Ha[1,*] 🔾    Nguyen Dinh Chau[2,*]    Bui Quang Bieu[2]    Mai Hong Son[1] 🔾

[1] Department of Nuclear Medicine, Hospital 108, Hanoi, Vietnam
[2] Department of Radiation Oncology and Radiosurgery, Hospital 108, Hanoi, Vietnam

Address for correspondence  Mai Hong Son, MD, PhD, Department of Nuclear Medicine, Hospital 108, Hanoi, Vietnam (e-mail: alex.hong.son@gmail.com).

## Abstract

**Objective**  The aim of this study is to determine prognostic values of sequential ^{18}F-FDG PET/CT metabolic parameters in locally advanced esophageal squamous cell carcinoma (ESCC) patients treated with definitive chemoradiotherapy.

**Materials and Methods**    Forty locally advanced ESCC patients treated with definitive chemoradiotherapy (dCRT) who received pre-treatment ^{18}F-FDG PET/CT (PET1) and 3-months post-treatment ^{18}F-FDG PET/CT (PET2) were enrolled in the prospective study. ^{18}F-FDG PET parameters of the primary tumor including maximum and mean standardized uptake values (SUVmax, SUVmean), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were calculated on PET delineated primary tumor. Using Kaplan-Meier curves to estimated overall survival (OS), progression-free survival (PFS), and local-regional control (LRC). Cox regression analysis was performed to find significant prognostic factors for survival.

**Keywords**
► ^{18}F-FDG PET/CT
► sequential metabolic parameter
► predictive value
► definitive chemoradiotherapy
► esophageal squamous cell carcinoma

**Results**    With a median follow-up of 13.5 months, the 4-year OS, PFS, and LRC rates were 67.3%, 52.6%, and 53.4% respectively. Patients with MTV 2 > 5.7 had lower OS, PFS, and LRC rates than the lower MTV 2 group ($p < 0.05$). Univariate Cox regression analysis showed that MTV2 was a significant prognostic factor for OS, PFS, and LRC ($p < 0.05$).

**Conclusion**    MTV parameter of sequential ^{18}F-FDG PET/CT could be used as a prognostic factor for OS, PFS, and LRC in locally advanced ESCC patients treated with dCRT.

## Introduction

Esophageal cancer is one of the most common cancers in the world.[1] Despite recent improvements in treatment modalities, overall survival (OS) remains poor. Upper-third esophageal carcinoma including cervical and upper thoracic tumor represents approximately 10% of esophageal cancer.[2] Surgery is considered a primary treatment modality for the middle and lower third esophageal tumors.[3] Meanwhile, radical surgery meets challenges in upper-third esophageal tumors due to the high risk of complications and death.

---

*  *These authors contributed equally to the study and retain the first authorship.*

Squamous cell carcinoma histologically accounts for over 90% of upper-third esophageal carcinoma that is sensitive to radio-chemotherapy. Therefore, definitive chemoradiation therapy (dCRT) is a standard treatment with improving survival in comparison with surgery or radiation therapy alone.[4–7]

It has been proved that $^{18}$F-flouro-2-deoxy-glucose positron emission tomography/computed tomography ($^{18}$F-FDG PET/CT) has an important role in staging, radiotherapy planning, restaging, and follow-up of esophageal cancer.[8,9] Esophageal tumors can be evaluated by endoscopy, ultrasound endoscopy, computed tomography, and $^{18}$F-FDG PET/CT.[10] Metabolic changes measured by $^{18}$F-FDG PET occur earlier than morphological changes. Therefore, $^{18}$F-FDG PET/CT can detect malignant tumor, recurrent or metastasis diseases earlier than conventional imaging.[11–13]

Recently, the prognostic role of $^{18}$F-FDG PET/CT has been increasingly investigated. Several papers have shown that pretreatment quantitative parameters derived from $^{18}$F-FDG PET/CT such as maximum standardized uptake value SUVmax, total lesion glycolysis (TLG), and metabolic tumor volume (MTV) were independent prognostic factors for treatment outcomes.[14–16] Besides that, sequential $^{18}$F-FDG PET/CT after dCRT seems to be a more promising tool in prognosis of outcomes. Some studies proved that sequential $^{18}$F-FDG PET/CT was helpful to evaluate the treatment outcomes as well as making decision to guide personalized therapy such as SUVs and tumor burden parameters.[17,18] Moreover, sequential SUVmax, TLG, and MTV were used as the primary parameter of quantitative $^{18}$F-FDG PET/CT in prognosis outcome in few studies.[19–21] A study of Kim et al showed that relative change of SUVmean and MTV is related to local–regional recurrences and distant metastases after radiation therapy.[22] Li et al reported that sequential TLG was more reliable than MTV in prognosis for outcome after dCRT.[17] However, the actual prognostic role of sequential $^{18}$F-FDG PET/CT parameters still being debated.[23]

In this study, we aimed to assess the potential value of sequential SUVs parameters, MTV, and TLG in prognosis of local–regional control (LRC), progression-free survival (PFS), and OS in upper-third esophageal squamous cell carcinoma (ESCC) patients after dCRT.

## Materials and Methods

### Patients' Population
A prospective study with 60 consecutive upper-third ESCC patients registered from May 2017 to November 2021 at 108 Military Central Hospital. The inclusion criteria were (1) upper third esophageal tumor, (2) squamous cell carcinoma confirmed by endoscopic biopsy, (3) stage II or III by American Joint Committee on Cancer 7th, and (4) Eastern Cooperative Oncology Group performance status: 0 to 2, (5) age more than or equal to 18 years. The exclusion criteria were (1) other serious comorbidities, (2) previous radiation or chemotherapy, (3) abdominal lymph-node metastasis, and (4) insufficient follow-up data (20 patients). Forty patients underwent dCRT and had two $^{18}$F-FDG PET/CT image series.

Whole body $^{18}$F-FDG PET/CT was performed within 2 weeks before dCRT, then sequential PET scan was repeated after treatment 12 weeks. The primary endpoint was OS and secondary endpoints were PFS and locoregional-free survival. This study was approved by the Institutional Review Board of Hospital 108 (No 127/QĐ-VNC). Written informed consent was obtained from all patients before registration.

### $^{18}$F-FDG PET/CT Procedure
All patients underwent whole-body $^{18}$F-FDG PET/CT in the Department of Nuclear Medicine, the Hospital 108. PET/CT scan was performed, using GE Discovery 710 (GE Healthcare, Milwaukee, Wisconsin, United States), according to the European Association of Nuclear Medicine guidelines, version 2.0.[24] Patients should be fasted at least 4 hours, and blood sugar was measured before injection of $^{18}$F-FDG. The PET/CT study schedule was postponed when glucose level higher than 11 mmol/L (about 200 mg/dL). Afterward, the patients rested in the waiting room before intravenous injection of 2.5 MBq/kg body weight ($\pm$10%) of $^{18}$F-FDG. The parameters of the low dose CT scan were as follows: 120 kVp, modulated milliampere-seconds (mAs), the helical slice thickness of 3.75 mm, and 0.5 s/rotation. PET images were reconstructed using an iterative algorithm with attenuation correction with CT.

### Quantitative $^{18}$F-FDG Metabolic Assessment
$^{18}$F-FDG PET/CT images were evaluated by two experienced nuclear medicine physicians and the consensus was reached in each case. The volume of interest was set manually to exclude adjacent physiological $^{18}$F-FDG-avid structures on attenuation-corrected PET images at the AW workstation version 4.7 (GE Healthcare, Milwaukee, Wisconsin, United States). Then, the region of interest in the esophageal lesions was assessed with reference to patient's symptoms, endoscopy, and CT imaging. The tumor volume was determined by iterative adaptive threshold segmentation provided by vendor (PETVCAR software, GE Healthcare). The iterative algorithm used a slope gradient vector algorithm which found a threshold value that separated the tumor from the background tissue by weighting the SUV max value within the bounding box by a "w" weight factor (where $0 \leq w \leq 1$ with default value of 0.5). The tumor border was then semiautomatically contoured and MTV was obtained as tumor volume (►**Supplement Fig. 1**). SUVmax and SUVmean were defined as the maximum and mean value of SUV in MTV. TLG was calculated as SUVmean multiplied by MTV. All $^{18}$F-FDG PET/CT derived parameters were computed by PETVCAR software (version 4.7, GE Healthcare, Milwaukee, Wisconsin, United States). $^{18}$F-FDG-avid lesions were defined as uptake above that of mediastinal blood pool activity, or above the background activity. In case of noncomplete response, both PET scans would be co-registered and the sequential parameters were identified by semiautomatic delineation method based on the original location of primary tumor with manual adjustment of esophagitis and physiological high uptake regions. Tumor's quantitative parameters were SUVmax, SUVmean, MTV, and TLG computed by PETVCAR software

**Table 1** General characteristic of esophageal squamous cell carcinoma patients

| Clinical characteristics | No. of patients ($n = 40$) | Percent (%) |
|---|---|---|
| Age (mean $\pm$ SD) | $58.0 \pm 7.6$ | |
| **Sex** | | |
| Male | 40 | 100 |
| **Tumor site** | | |
| Cervical | 12 | 30.0 |
| Thorax | 28 | 70.0 |
| **Pathology** | | |
| Highly differentiated (G1) | 2 | 5.0 |
| Moderately differentiated (G2) | 20 | 50.0 |
| Poorly differentiated (G3) | 17 | 42.5 |
| Unclassified (GX) | 1 | 2.5 |
| **T stage** | | |
| T1b | 2 | 5.0 |
| T2 | 3 | 7.5 |
| T3 | 35 | 87.5 |
| **N stage** | | |
| N0 | 4 | 10.0 |
| N1 | 23 | 57.5 |
| N2 | 11 | 27.5 |
| N3 | 2 | 5.0 |
| **TNM stage** | | |
| IIA | 1 | 2.5 |
| IIB | 5 | 12.5 |
| IIIA | 22 | 55.5 |
| IIIB | 10 | 25.0 |
| IIIC | 2 | 5.0 |
| **Chemotherapy regimen** | | |
| Cisplatin/5-FU | 6 | 15.0 |
| Paclitaxel/carboplatin | 34 | 85.0 |
| Interval time between the end of dCRT and PET2 (months) | $3.3 \pm 0.2$ | |
| Follow-up median (months) | 13.5 (6–50) | |

Abbreviations: 5-FU, fluorouracil; dCRT, definitive chemoradiation therapy; PET2, positron emission tomography2; SD, standard deviation.

(version 4.7, GE Healthcare, Milwaukee, Wisconsin, United States).[25] Derived parameters were collected on pretreatment ^{18}F-FDG PET/CT: SUVmax1, SUVmean1, MTV1, TLG1, and posttreatment: SUVmax2, SUVmean2, MTV2, TLG2 (►**Supplement Fig. 2**).

### Chemoradiation Therapy
dCRT was approved by tumor board in oncology institute of the Hospital 108. Gross tumor volumes were identified by the combination of contrast-enhanced CT simulation and ^{18}F-FDG PET/CT. Intensity-modulated radiation therapy (IMRT) with simultaneous integrated boost technique delivers a total dose of 60 Gy to the primary tumor and active lymph nodes, 50.4 Gy to regional lymph nodes in 28 fractions. Chemotherapy was administered with cisplatin 75 mg/m$^2$ day 1 plus fluorouracil (5-FU) 750 mg/m$^2$ from day 1 to 4 (weeks 1, 5, 9, 13) or paclitaxel 50 mg/m$^2$ plus carboplatin AUC2 (days 1, 8, 15, 22, 29).

### Follow-Up
Sequential ^{18}F-FDG PET/CT was assessed 3 months after completion of dCRT. Patients were followed up every 3 months with clinical examination, esophageal endoscopy, and chest-abdominal CT. After 2 years, the patients underwent follow-up every 6 months. OS was defined as the time from the start of dCRT to death of any cause or the last day of clinical follow-up. PFS was defined as the time from the beginning of dCRT to the day of disease progression or death of any cause or the last day of clinical follow-up. LRC was the length of time from the start of treatment to the day of progression or recurrence within irradiated field.

### Statistical Analysis
Commercial software packages were used for statistical analysis (SPSS v.22.0, IBM Corp). Categorical values were compared using the chi-square test or Fisher's exact test. Continuous variables were compared using paired Student's $t$-test with normal distribution or Mann–Whitney U test with abnormal distribution.[26] Estimating LRC, PFS, and OS was analyzed by using Kaplan–Meier methods. Cox regression analysis was used to determine the prognostic parameters for OS, PFS, and LRC. Mean value of FDG PET/CT parameters were used to identify cutoff values for OS, PFS, and LRC. The statistical significance was set at $p$-value less than 0.05.[27]

**Table 2** Changes of tumor parameters between initial and sequential $^{18}$F-FDG PET/CT

|  | PET 1 | | | PET 2 | | | $p$-Value |
|---|---|---|---|---|---|---|---|
|  | Mean | Median | Range | Mean | Median | Range |  |
| SUVmax | 14.5 | 13.6 | 2.9–34.1 | 5.5 | 4.0 | 1.6–20.9 | 0.000[a] |
| SUVmean | 6.7 | 7.0 | 2.3–15.1 | 3.1 | 2.9 | 1.3–8.7 | 0.000[a] |
| MTV | 18.6 | 13.7 | 0.9–55.3 | 5.7 | 1.7 | 0.1–32.5 | 0.000[a] |
| TLG | 151.3 | 96.3 | 2.2–778.4 | 27.4 | 5.0 | 0.2–283.8 | 0.000[a] |

Abbreviations: $^{18}$F-FDG PET/CT, $^{18}$F-flouro-2-deoxy-glucose positron emission tomography/computed tomography; MTV, metabolic tumor volume; SUVmax, maximum standardized uptake value; TLG, total lesion glycolysis.
[a]Mann–Whitney U test.

## Results

### Patients' Characteristics

The general characteristics of patients was summarized in ►**Table 1**. Forty consecutive patients, 100% male with mean age of 58, were included in the study. The majority of patients 34/40 (85.5%) were classified with stage III. Paclitaxel/carboplatin regimen was administered in 85% of patients. During the median follow-up of 13.5 months, 10 patients were death. Causes of death were tumor progression (7 patients), lung metastasis (2 patients), and esophageal perforation (1 patient).

### The Prognostic Value of Sequential $^{18}$F-FDG PET/CT Parameters for LRC, PFS, OS

The tumor metabolic parameters derived from PET 1 and PET 2 were showed in ►**Table 2**. The 4-year OS, PFS, and LRC rate were 67.3, 52.6, and 53.4%, respectively (►**Fig. 1**). On Cox regression univariate analysis, MTV2 was a significant prognosis factor for OS (heart rate [HR] = 1.07, $p = 0.022$), PFS (HR = 1.05, $p = 0.045$), and LRC (HR = 1.07, $p = 0.005$) (►**Table 3**). The median OS, PFS, and LRC of patients with MTV2 of 5.7 mL or higher were 13, 7, and 8 months, respectively, which were significantly worse than that of patients with MTV2 less than 5.7 mL ($p < 0.05$; ►**Fig. 2**).

## Discussion

Definitive chemoradiation is the first-choice treatment of inoperable esophageal cancer, especially in patients with squamous cell carcinoma. Despite the improvement in radiotherapy techniques such as IMRT, the outcomes of ESCC patients remain poor with 5-year OS around 25 to 31%.[28,29] Tumor stage and lymph node involvement are two well-known prognostic factors of esophageal cancer.[30,31] Other clinical factors could impact on OS including malnutrition, comorbidities, and low socioeconomic status.[32] Our study showed clinical staging, tumor histological grading, and chemo regimen were not significant prognostic factors for survival ($p > 0.05$). The primary tumor and nodal status of patients in our study could not be confirmed by pathology that might lead to inaccurate in assessment of clinical staging and histological grading. Our result is in line with previous study that showed comparable OS between carboplatin/paclitaxel and cisplatin/5-FU as dCRT in esophageal cancer patients.[33]

Prognostic role of $^{18}$F-FDG PET/CT has been investigated in recent studies. But which parameters derived from $^{18}$F-FDG PET/CT should be used as prognostic factors for survival in esophageal cancer is still matter of debate. Our study reported that posttreatment MTV (MTV 2) was a significant factor in prognosis of LRC, PFS, and OS by univariate Cox



**Fig. 1** Kaplan–Meier curve for survival. LRC, locoregional recurrence; OS, overall survival; PFS, progression-free survival.

**Table 3** Univariate Cox regression analysis for OS, PFS, and LRC in ESCC patients treated with dCRT

| Parameters | OS | | | PFS | | | LRC | | |
|---|---|---|---|---|---|---|---|---|---|
| | HR | 95% CI | *p*-Value | HR | 95% CI | *p*-Value | HR | 95% CI | *p*-Value |
| Stage III/ II | 28.37 | 0.31–25,959.87 | 0.336 | 3.47 | 0.46–26.12 | 0.228 | 1.37 | 0.48–3.95 | 0.560 |
| Pathology G3/G1-2 | 2.06 | 0.58–7.31 | 0.263 | 1.55 | 0.60–4.02 | 0.368 | 0.83 | 0.30–2.34 | 0.728 |
| Chemo CF/PC | 2.79 | 0.72–10.86 | 0.138 | 1.68 | 0.55–5.12 | 0.358 | 1.33 | 0.38–4.68 | 0.655 |
| SUVmax1 | 1.06 | 0.97–1.15 | 0.182 | 1.05 | 0.98–1.12 | 0.148 | 1.05 | 0.98–1.13 | 1.146 |
| SUVmean 1 | 1.32 | 0.99–1.53 | 0.061 | 1.12 | 0.95–1.31 | 0.173 | 1.12 | 0.93–1.34 | 0.234 |
| MTV 1 | 1.04 | 1.00–1.07 | 0.044* | 1.02 | 0.99–1.05 | 0.193 | 1.02 | 0.98–1.05 | 0.408 |
| TLG 1 | 1.00 | 1.00–1.01 | 0.060 | 1.00 | 1.00–1.01 | 0.237 | 1.00 | 1.00–1.01 | 0.322 |
| SUVmax 2 | 1.12 | 0.98–1.27 | 0.094 | 1.08 | 1.0–1.18 | 0.070 | 1.12 | 1.02–1.22 | 0.013* |
| SUVmean 2 | 1.28 | 0.87–1.88 | 0.209 | 1.26 | 0.99–1.59 | 0.057 | 1.39 | 1.10–1.77 | 0.006* |
| MTV 2 | 1.07 | 1.01–1.13 | 0.022* | 1.05 | 1.00–1.09 | 0.045* | 1.07 | 1.02–1.12 | 0.005* |
| TLG 2 | 1.01 | 0.99–1.02 | 0.092 | 1.00 | 0.99–1.01 | 0.258 | 1.01 | 1.00–1.01 | 0.181 |

Abbreviations: CI, confidence interval; dCRT, definitive chemoradiation therapy; ESCC, esophageal squamous cell carcinoma; HR, heart rate; LRC, locoregional recurrence; MTV1, metabolic tumor volume1; OS, overall survival; PFS, progression-free survival; SUVmax 1, maximum standardized uptake value 1; TLG 1, total lesion glycolysis 1.
*denotes significant difference.



**Fig. 2** Kaplan–Meier curves for overall survival, progression-free survival, and local–regional control according to metabolic tumor volume 2 more than or equal to 5.7 and less than 5.7 mL. MTV 2, metabolic tumor volume 2.

regression analysis. Patients with MTV 2 more than 5.7 had worse OS, PFS, and LCR than that with MTV 2 of 5.7 or less ($p < 0.05$). MTV reflects the active metabolic state of the whole tumor and it is considered to be a comprehensive parameter in prediction of treatment response and prognosis. Hence, this parameter may represent the shrinkage of the viable tumor portion after chemo and/or radiation therapy. Some studies showed that MTV was better than SUVmax that represents a small part of tumor in prognosis of esophageal cancer.[20,34–36] MTV2 shows the volume of metabolic lesion that remains after therapy and it may have value in prognosis of treatment response and outcome. Moreover, Tamandl et al founded that MTV2 with cutoff value of 5.8 could predict pathological complete response that correlated to OS.[37] Prognostic role of other $^{18}$F-FDG PET/CT parameters was mentioned in some studies. The optimal cutoff prognostic

value of SUVs, MTV, and TLG varied across studies because they may depend on histopathologic features, necrosis, heterogeneity of tumor, and methods of segmentation.[38–40] Li et al reported that SUVmax 2, TNM, and length of primary tumor were independent prognostic factors for OS.[17] This study used 40% of SUVmax as the lower threshold for MTV calculations, which included primary tumor and lymph node with highest SUVmax. In our study, MTV was determined by iterative adaptive threshold method that has been proved more accurate than fix threshold method.[41]

MTV and TLG are emerging new parameters, and they seem to have more promising results in prognosis than other parameters.[17,19,21,22,42] The prognostic value of these parameters for treatment outcome was approved in laryngeal carcinoma and nonsmall cell lung cancer in recent studies.[43,44] A systemic review of Cremonesi et al showed

**Table 4** Sequential $^{18}$F-FDG PET/CT parameters and clinical outcomes among studies

| Author, year | No. of patients/Study style | Pathology | Protocol | Prognostic factors | Cutoff value | Outcomes |
|---|---|---|---|---|---|---|
| Chen et al[46] 2015 | 34 Prospective | SCC | dCRT | MTV 1 ΔSUVmax | 21 mL 70% | PFS PFS, LRC |
| Li et al[17] 2015 | 160 Retrospective | SCC | dCRT | MTV 1 TLG 1 ΔSUVmax | 22 mL 170 67% | OS OS OS |
| Kim et al[42] 2016 | 53 Retrospective | AC | CRT + Sur | ΔTLG ΔMTV ΔSUVmax | 44.4% 25.5% 23.5% | OS |
| Li et al[21] 2019 | 134 Retrospective | SCC | dCRT | MTV 1 TLG1 SUVmax 2 TLG 2 | 10.5 mL 59.8 7.8 44.3 | OS OS OS OS |
| Kim et al[22] 2019 | 21 Retrospective | SCC | CRT +/− Sur | ΔMTV ΔSUVmean | 1.14 35% | LRC DM |

Abbreviations: dCRT, definitive chemoradiation therapy; DM, distant metastasis; LRC, locoregional recurrence; MTV1, metabolic tumor volume 1; OS, overall survival; PFS, progression-free survival; PFS, progression-free survival; SCC, squamous cell carcinoma; Sur, surgery; SUVmax 1, maximum standardized uptake value 1; TLG 1, total lesion glycolysis 1.

that there were not constant correlation between sequential $^{18}$F-FDG PET/CT parameters and clinical outcomes among studies (►**Table 4**).[45] Therefore, further research is needed with uniform protocol and method of analysis to assess prognostic value of sequential $^{18}$F-FDG PET/CT.

Several studies demonstrated that pretreatment $^{18}$F-FDG PET/CT parameters such as SUVmax, MTV, and TLG of primary tumor were independent prognostic factors for treatment outcomes.[14–16,21,46] Our result showed only MTV 1 had prognostic value for OS in univariate analysis. Posttreatment residual lesion is the part of the primary tumor that is resistant to chemoradiotherapy and might directly cause recurrent or metastasis.[22] Therefore, sequential $^{18}$F-FDG PET/CT might be more promising tool than pretreatment $^{18}$F-FDG PET/CT in prognosis of outcomes. The prognostic role of sequential $^{18}$F-FDG PET/CT in our study was in line with several studies.[21,22,42]

Our study had some limitations. First, this is a single-center study that may had inherent biases. Second, metabolic parameters of sequential FDG PET/CT do not accurately reflect the effectiveness of treatment due to postradiation inflammation. In addition, only parameters of the primary tumor were evaluated, while the outcomes of ESCC actually correlated to both tumor and metastatic lymph node parameters. Moreover, the number of patient enrollment is limited and the time of follow-up is less than 5 years. Those explain why we did not find any independent prognostic factor for survival when performing multivariate Cox regression analysis in our study.

## Conclusion

Our study suggests that posttreatment MTV (MTV2) with a cutoff value of 5.7 mL can be used to prognose clinical outcomes in locally advanced ESCC patients treated with dCRT. These findings need to be validated by further studies with a larger cohort of patients.

## References

1 Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71(03): 209–249

2 Ding X, Zhang J, Li B, et al. A meta-analysis of lymph node metastasis rate for patients with thoracic oesophageal cancer and its implication in delineation of clinical target volume for radiation therapy. Br J Radiol 2012;85(1019):e1110–e1119

3 Ajani JA, Barthel JS, Bentrem DJ, et al; National Comprehensive Cancer Network. Esophageal and esophagogastric junction cancers. J Natl Compr Canc Netw 2011;9(08):830–887

4 Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol 2012;19(01):68–74

5 Burmeister BH, Dickie G, Smithers BM, Hodge R, Morton K. Thirty-four patients with carcinoma of the cervical esophagus treated with chemoradiation therapy. Arch Otolaryngol Head Neck Surg 2000;126(02):205–208

6 Kato K, Muro K, Minashi K, et al; Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group (JCOG) Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int J Radiat Oncol Biol Phys 2011;81(03):684–690

7 van Hagen P, Hulshof MCCM, van Lanschot JJB, et al; CROSS Group. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012;366(22):2074–2084

8 Kumar P, Damle NA, Bal C. Role of F18-FDG PET/CT in the staging and restaging of esophageal cancer: a comparison with CECT. Indian J Surg Oncol 2011;2(04):343–350

9 Muijs CT, Beukema JC, Pruim J, et al. A systematic review on the role of FDG-PET/CT in tumour delineation and radiotherapy planning in patients with esophageal cancer. Radiother Oncol 2010;97(02):165–171

10 Bruzzi JF, Munden RF, Truong MT, et al. PET/CT of esophageal cancer: its role in clinical management. Radiographics 2007;27(06):1635–1652

11 Gopal A, Xi Y, Subramaniam RM, Pinho DF. Intratumoral metabolic heterogeneity and other quantitative ^{18}F-FDG PET/CT parameters for prognosis prediction in esophageal cancer. Radiol Imaging Cancer 2020;3(01):e200022

12 Han S, Kim YJ, Woo S, Suh CH, Lee JJ. Prognostic value of volumetric parameters of pretreatment 18F-FDG PET/CT in esophageal cancer: a systematic review and meta-analysis. Clin Nucl Med 2018;43(12):887–894

13 Shum WY, Ding HJ, Liang JA, Yen KY, Chen SW, Kao CH. Use of pretreatment metabolic tumor volumes on PET-CT to predict the survival of patients with squamous cell carcinoma of esophagus treated by curative surgery. Anticancer Res 2012;32(09):4163–4168

14 Atsumi K, Nakamura K, Abe K, et al. Prediction of outcome with FDG-PET in definitive chemoradiotherapy for esophageal cancer. J Radiat Res (Tokyo) 2013;54(05):890–898

15 Rizk NP, Tang L, Adusumilli PS, et al. Predictive value of initial PET-SUVmax in patients with locally advanced esophageal and gastroesophageal junction adenocarcinoma. J Thorac Oncol 2009;4(07):875–879

16 Suzuki A, Xiao L, Hayashi Y, et al. Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy. Cancer 2011;117(21):4823–4833

17 Li Y, Zschaeck S, Lin Q, Chen S, Chen L, Wu H. Metabolic parameters of sequential 18F-FDG PET/CT predict overall survival of esophageal cancer patients treated with (chemo-) radiation. Radiat Oncol 2019;14(01):35

18 Wieder HA, Ott K, Lordick F, et al. Prediction of tumor response by FDG-PET: comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction. Eur J Nucl Med Mol Imaging 2007;34(12):1925–1932

19 Chang S, Koo PJ, Kwak JJ, Kim SJ. Changes in total lesion glycolysis evaluated by repeated F-18 FDG PET/CT as prognostic factor in locally advanced esophageal cancer patients treated with preoperative chemoradiotherapy. Oncology 2016;90(02):97–102

20 Hatt M, Visvikis D, Albarghach NM, Tixier F, Pradier O, Cheze-le Rest C. Prognostic value of 18F-FDG PET image-based parameters in oesophageal cancer and impact of tumour delineation methodology. Eur J Nucl Med Mol Imaging 2011;38(07):1191–1202

21 Li Y, Lin Q, Wang L, et al. Application of sequential (18)F-FDG PET/CT scans for concurrent chemoradiotherapy of non-surgical squamous cell esophageal carcinoma. J BUON 2014;19(02):517–523

22 Kim N, Cho H, Yun M, Park KR, Lee CG. Prognostic values of mid-radiotherapy ^{18}F-FDG PET/CT in patients with esophageal cancer. Radiat Oncol 2019;14(01):27

23 Omloo JMT, van Heijl M, Hoekstra OS, van Berge Henegouwen MI, van Lanschot JJB, Sloof GW. FDG-PET parameters as prognostic factor in esophageal cancer patients: a review. Ann Surg Oncol 2011;18(12):3338–3352

24 Boellaard R, Delgado-Bolton R, Oyen WJG, et al; European Association of Nuclear Medicine (EANM) FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 2015;42(02):328–354

25 Larson SM, Erdi Y, Akhurst T, et al. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. The visual response score and the change in total lesion glycolysis. Clin Positron Imaging 1999;2(03):159–171

26 Milenović Ž Application of Mann-Whitney U test in research of professional training of primary school teachers. Metod Obz Horiz 2011;6(01):73–79

27 Grabowski B. "P < 0.05" might not mean what you think: American Statistical Association clarifies p values. J Natl Cancer Inst 2016;108(08):djw194

28 Cooper JS, Guo MD, Herskovic A, et al; Radiation Therapy Oncology Group. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). JAMA 1999;281(17):1623–1627

29 Shi A, Liao Z, Allen PK, et al. Long-term survival and toxicity outcomes of intensity modulated radiation therapy for the treatment of esophageal cancer: a large single-institutional cohort study. Adv Radiat Oncol 2017;2(03):316–324

30 Bouvier AM, Binquet C, Gagnaire A, Jouve JL, Faivre J, Bedenne L. Management and prognosis of esophageal cancers: has progress been made? Eur J Cancer 2006;42(02):228–233

31 Mariette C, Piessen G, Briez N, Triboulet JP. The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent. Ann Surg 2008;247(02):365–371

32 Vendrely V, Launay V, Najah H, Smith D, Collet D, Gronnier C. Prognostic factors in esophageal cancer treated with curative intent. Dig Liver Dis 2018;50(10):991–996

33 Honing J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients. Ann Oncol 2014;25(03):638–643

34 Cervino AR, Evangelista L, Alfieri R, et al. Positron emission tomography/computed tomography and esophageal cancer in the clinical practice: how does it affect the prognosis? J Cancer Res Ther 2012;8(04):619–625

35 Hatt M, Majdoub M, Vallières M, et al. 18F-FDG PET uptake characterization through texture analysis: investigating the complementary nature of heterogeneity and functional tumor volume in a multi-cancer site patient cohort. J Nucl Med 2015;56(01):38–44

36 Nakajo M, Jinguji M, Nakabeppu Y, et al. Texture analysis of ^{18}F-FDG PET/CT to predict tumour response and prognosis of patients with esophageal cancer treated by chemoradiotherapy. Eur J Nucl Med Mol Imaging 2017;44(02):206–214

37 Tamandl D, Fueger B, Haug A, et al. A diagnostic algorithm that combines quantitative 18F-FDG PET parameters and contrast-

enhanced CT improves posttherapeutic locoregional restaging and prognostication of survival in patients with esophageal cancer. Clin Nucl Med 2019;44(01):e13–e21

38 Adams MC, Turkington TG, Wilson JM, Wong TZ. A systematic review of the factors affecting accuracy of SUV measurements. AJR Am J Roentgenol 2010;195(02):310–320

39 Koopman D, Jager PL, Slump CH, Knollema S, van Dalen JA. SUV variability in EARL-accredited conventional and digital PET. EJNMMI Res 2019;9(01):106

40 Nahmias C, Wahl LM. Reproducibility of standardized uptake value measurements determined by 18F-FDG PET in malignant tumors. J Nucl Med 2008;49(11):1804–1808

41 Tamal M. Intensity threshold based solid tumour segmentation method for Positron Emission Tomography (PET) images: a review. Heliyon 2020;6(10):e05267

42 Kim SJ, Koo PJ, Chang S. Predictive value of repeated F-18 FDG PET/CT parameters changes during preoperative chemoradiotherapy to predict pathologic response and overall survival in locally advanced esophageal adenocarcinoma patients. Cancer Chemother Pharmacol 2016;77(04):723–731

43 Al-Ibraheem A, Abdlkadir AS, Al-Adhami D, et al. The prognostic and diagnostic value of [18F]FDG PET/CT in untreated laryngeal carcinoma. J Clin Med 2023;12(10):3514

44 Berkowitz AC, Halmos B, Cheng H, Huntzinger C, Ohri N. FDG-PET metrics in advanced non-small cell lung cancer (NSCLC): a review and meta-analysis. Clin Transl Imaging. Doi: 10.1007/s40336-023-00542-y

45 Cremonesi M, Garibaldi C, Timmerman R, et al. Interim ^{18}F-FDG-PET/CT during chemo-radiotherapy in the management of oesophageal cancer patients. A systematic review. Radiother Oncol 2017;125(02):200–212

46 Chen H, Li Y, Wu H, et al. 3′-deoxy-3′-[18F]-fluorothymidine PET/CT in early determination of prognosis in patients with esophageal squamous cell cancer: comparison with [18F]-FDG PET/CT. Strahlenther Onkol 2015;191(02):141–152